Turn Therapeutics has already transitioned into a publicly traded corporate entity, having officially commenced trading of its common stock on the Nasdaq exchange. The company executed this strategic milestone through a direct listing of its existing shares rather than a traditional initial public offering designed to raise fresh capital. This market debut was closely tied to securing a significant financing commitment from institutional alternative lenders to fund ongoing clinical trials, regulatory submissions, and commercial scaling operations for its proprietary anti-infective and dermatological technology platforms.